Skip to Main Navigation
Skip to Page Content
Share This:
https://ntp.niehs.nih.gov/go/1251

TDMS Study 05161-06 Pathology Tables

NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00
Route: GAVAGE                                                                                                     Time: 08:16:00

                                                          MICE/FINAL#1




       Facility:  Southern Research Institute

       Chemical CAS #:  23246-96-0

       Lock Date:  11/17/99

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0            3.0                                                                 
                                                   MG/KG/DY     MG/KG/DY                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50                                                               
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 9           25                                                               
    Natural Death                                      3            8                                                               
    Accidently Killed                                  4                                                                            
  Survivors                                                                                                                         
    Natural Death                                                   1                                                               
    Terminal Sacrifice                                34           16                                                               
                                                                                                                                    
  Animals Examined Microscopically                    50           50                                                               
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Gallbladder                                        (45)         (45)                                                             
      Histiocytic Sarcoma                              1 (2%)                                                                       
      Sarcoma                                          1 (2%)                                                                       
   Intestine Large, Colon                             (49)         (47)                                                             
   Intestine Large, Cecum                             (48)         (47)                                                             
      Histiocytic Sarcoma                              1 (2%)       1 (2%)                                                          
   Intestine Small, Jejunum                           (43)         (45)                                                             
      Histiocytic Sarcoma                              1 (2%)                                                                       
   Intestine Small, Ileum                             (46)         (46)                                                             
   Liver                                              (49)         (50)                                                             
      Cholangioma                                                   1 (2%)                                                          
      Hemangiosarcoma                                               1 (2%)                                                          
      Hepatocellular Carcinoma                         7 (14%)                                                                      
      Hepatocellular Carcinoma, Multiple               1 (2%)                                                                       
      Hepatocellular Adenoma                           7 (14%)                                                                      
      Hepatocellular Adenoma, Multiple                 2 (4%)                                                                       
      Histiocytic Sarcoma                              1 (2%)       2 (4%)                                                          
      Sarcoma, Multiple                                1 (2%)                                                                       
   Mesentery                                          (23)         (29)                                                             
      Carcinoma, Metastatic, Kidney                                 1 (3%)                                                          
      Hemangioma                                                    1 (3%)                                                          
      Histiocytic Sarcoma                              1 (4%)       1 (3%)                                                          
      Sarcoma                                                       1 (3%)                                                          
      Sarcoma, Multiple                                1 (4%)                                                                       
   Pancreas                                           (49)         (50)                                                             
      Histiocytic Sarcoma                              1 (2%)       1 (2%)                                                          
      Sarcoma, Multiple                                1 (2%)                                                                       
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0            3.0                                                                 
                                                   MG/KG/DY     MG/KG/DY                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - cont                                                                                                            
   Salivary Glands                                    (50)         (50)                                                             
   Stomach, Forestomach                               (49)         (49)                                                             
   Stomach, Glandular                                 (49)         (48)                                                             
      Histiocytic Sarcoma                                           1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (50)                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (50)         (50)                                                             
      Histiocytic Sarcoma                              1 (2%)       1 (2%)                                                          
   Adrenal Medulla                                    (49)         (49)                                                             
   Pituitary Gland                                    (48)         (49)                                                             
      Adenoma                                                       1 (2%)                                                          
      Pars Distalis, Adenoma                           5 (10%)      1 (2%)                                                          
   Thyroid Gland                                      (49)         (50)                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (49)         (49)                                                             
      Duct, Carcinoma                                  1 (2%)                                                                       
   Ovary                                              (49)         (48)                                                             
      Cystadenoma                                      1 (2%)                                                                       
      Granulosa Cell Tumor Benign                                   1 (2%)                                                          
      Luteoma                                                       1 (2%)                                                          
   Uterus                                             (49)         (50)                                                             
      Hemangioma                                                    1 (2%)                                                          
      Histiocytic Sarcoma                                           1 (2%)                                                          
      Leiomyosarcoma                                                1 (2%)                                                          
      Endometrium, Adenoma                             1 (2%)                                                                       
      Endometrium, Polyp Stromal                                    1 (2%)                                                          
   Vagina                                                          (2)                                                              
      Sarcoma                                                       1 (50%)                                                         
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0            3.0                                                                 
                                                   MG/KG/DY     MG/KG/DY                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)         (50)                                                             
      Carcinoma, Metastatic, Kidney                                 1 (2%)                                                          
      Histiocytic Sarcoma                                           1 (2%)                                                          
   Lymph Node                                         (7)          (15)                                                             
      Iliac, Histiocytic Sarcoma                       1 (14%)                                                                      
      Mediastinal, Histiocytic Sarcoma                 1 (14%)      1 (7%)                                                          
      Pancreatic, Histiocytic Sarcoma                  1 (14%)                                                                      
      Pancreatic, Sarcoma                              1 (14%)                                                                      
      Renal, Histiocytic Sarcoma                       1 (14%)                                                                      
   Lymph Node, Mandibular                             (48)         (47)                                                             
      Histiocytic Sarcoma                              1 (2%)                                                                       
   Lymph Node, Mesenteric                             (48)         (49)                                                             
      Histiocytic Sarcoma                              1 (2%)       1 (2%)                                                          
   Spleen                                             (49)         (50)                                                             
      Hemangiosarcoma                                               1 (2%)                                                          
      Histiocytic Sarcoma                              1 (2%)       1 (2%)                                                          
      Plasma Cell Tumor Malignant                                   1 (2%)                                                          
   Thymus                                             (49)         (39)                                                             
      Histiocytic Sarcoma                                           1 (3%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (49)         (50)                                                             
      Adenoma                                                       1 (2%)                                                          
      Carcinoma                                                     2 (4%)                                                          
   Skin                                               (50)         (50)                                                             
      Subcutaneous Tissue, Sarcoma                     3 (6%)       2 (4%)                                                          
      Subcutaneous Tissue, Sarcoma, Multiple                        1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)         (50)                                                             
      Cranium, Carcinoma, Metastatic, Harderian                                                                                     
          Gland                                        1 (2%)                                                                       
   Skeletal Muscle                                    (1)          (3)                                                              
      Histiocytic Sarcoma                                           1 (33%)                                                         
      Sarcoma, Multiple                                1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0            3.0                                                                 
                                                   MG/KG/DY     MG/KG/DY                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (50)         (50)                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (50)                                                             
      Alveolar/Bronchiolar Adenoma                     1 (2%)       9 (18%)                                                         
      Alveolar/Bronchiolar Carcinoma                                3 (6%)                                                          
      Alveolar/Bronchiolar Carcinoma, Multiple         1 (2%)       1 (2%)                                                          
      Carcinoma, Metastatic, Harderian Gland           1 (2%)                                                                       
      Histiocytic Sarcoma                              1 (2%)       1 (2%)                                                          
      Sarcoma, Metastatic, Skin                                     1 (2%)                                                          
      Sarcoma, Metastatic, Uncertain Primary Site      1 (2%)                                                                       
      Mediastinum, Carcinoma, Metastatic, Kidney                    1 (2%)                                                          
   Nose                                               (50)         (50)                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (4)          (5)                                                              
      Adenoma                                          2 (50%)      3 (60%)                                                         
      Carcinoma                                        2 (50%)      1 (20%)                                                         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (49)         (50)                                                             
      Carcinoma, Metastatic, Mammary Gland                          1 (2%)                                                          
      Histiocytic Sarcoma                              1 (2%)       2 (4%)                                                          
      Osteosarcoma                                                  1 (2%)                                                          
   Ureter                                                          (1)                                                              
      Carcinoma, Metastatic, Kidney                                 1 (100%)                                                        
   Urinary Bladder                                    (50)         (48)                                                             
      Sarcoma                                          1 (2%)                                                                       
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0            3.0                                                                 
                                                   MG/KG/DY     MG/KG/DY                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)                                                             
      Histiocytic Sarcoma                              1 (2%)       2 (4%)                                                          
      Lymphoma Malignant                               7 (14%)      9 (18%)                                                         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0            3.0                                                                 
                                                   MG/KG/DY     MG/KG/DY                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            31          33                                                               
     Total Primary Neoplasms                           49          49                                                               
                                                                                                                                    
   Total Animals with Benign Neoplasms                 15          17                                                               
     Total Benign Neoplasms                            19          21                                                               
                                                                                                                                    
   Total Animals with Malignant Neoplasms              21          20                                                               
     Total Malignant Neoplasms                         30          28                                                               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              2           3                                                               
     Total Metastatic Neoplasm                          3           6                                                               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0            0.1          0.3          1.0          3.0                          
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50           50           50           50                        
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 4            6            3            6           13                        
    Natural Death                                      6            3            7            6           17                        
    Accidently Killed                                  1                                                                            
  Survivors                                                                                                                         
    Terminal Sacrifice                                39           41           40           38           18                        
    Natural Death                                                                                          2                        
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           50           50                        
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Esophagus                                          (50)         (50)         (50)         (50)         (50)                      
   Gallbladder                                        (44)         (43)         (36)         (41)         (38)                      
      Histiocytic Sarcoma                                           1 (2%)                                                          
   Intestine Large, Cecum                             (44)         (47)         (44)         (48)         (39)                      
      Carcinoma                                                                  1 (2%)                                             
      Histiocytic Sarcoma                                                                     1 (2%)                                
      Serosa, Hepatoblastoma, Metastatic, Liver                                               1 (2%)                                
   Intestine Small, Duodenum                          (45)         (48)         (47)         (47)         (40)                      
      Polyp Adenomatous                                                                       1 (2%)                                
   Intestine Small, Jejunum                           (45)         (47)         (44)         (47)         (39)                      
      Carcinoma                                                                  1 (2%)       2 (4%)                                
   Intestine Small, Ileum                             (44)         (49)         (44)         (47)         (41)                      
      Histiocytic Sarcoma                                           1 (2%)                                                          
   Liver                                              (50)         (50)         (50)         (50)         (50)                      
      Hemangiosarcoma                                  2 (4%)       1 (2%)                    2 (4%)      14 (28%)                  
      Hemangiosarcoma, Multiple                                                                           17 (34%)                  
      Hepatoblastoma                                   3 (6%)       2 (4%)                    1 (2%)                                
      Hepatocellular Carcinoma                         7 (14%)     11 (22%)     10 (20%)     15 (30%)      3 (6%)                   
      Hepatocellular Carcinoma, Multiple              16 (32%)     10 (20%)      9 (18%)      5 (10%)                               
      Hepatocellular Adenoma                          13 (26%)     10 (20%)     12 (24%)      5 (10%)                               
      Hepatocellular Adenoma, Multiple                 3 (6%)       8 (16%)      2 (4%)                                             
      Histiocytic Sarcoma                                           3 (6%)       2 (4%)       3 (6%)                                
      Leiomyosarcoma                                                             1 (2%)                                             
      Sarcoma, Metastatic, Skeletal Muscle                                                                 1 (2%)                   
   Mesentery                                          (12)         (10)         (9)          (14)         (6)                       
      Hemangiosarcoma                                                                                      1 (17%)                  
      Hemangiosarcoma, Metastatic, Liver               1 (8%)                                                                       
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0            0.1          0.3          1.0          3.0                          
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - cont                                                                                                            
      Hepatoblastoma, Metastatic, Liver                                                       1 (7%)                                
      Hepatocellular Carcinoma, Metastatic, Liver                                             2 (14%)                               
      Histiocytic Sarcoma                                           2 (20%)                   3 (21%)                               
      Leiomyosarcoma                                                             1 (11%)                                            
      Sarcoma, Metastatic, Skeletal Muscle                                                                 1 (17%)                  
   Pancreas                                           (49)         (50)         (50)         (50)         (48)                      
      Hepatoblastoma, Metastatic, Liver                                                       1 (2%)                                
      Histiocytic Sarcoma                                           3 (6%)                    1 (2%)                                
      Leiomyosarcoma                                                             1 (2%)                                             
   Salivary Glands                                    (50)         (50)         (50)         (50)         (50)                      
   Stomach, Forestomach                               (49)         (50)         (50)         (50)         (49)                      
      Leiomyosarcoma                                                             1 (2%)                                             
      Squamous Cell Papilloma                          1 (2%)                                 1 (2%)                                
   Stomach, Glandular                                 (47)         (48)         (49)         (49)         (46)                      
      Leiomyosarcoma                                                             1 (2%)                                             
   Tooth                                              (24)         (15)         (18)         (4)          (4)                       
      Peridontal Tissue, Fibrosarcoma                                            1 (6%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (50)         (50)         (50)         (50)                      
      Hepatoblastoma, Metastatic, Liver                                                       1 (2%)                                
      Histiocytic Sarcoma                                                                     1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (49)         (49)         (50)         (50)         (49)                      
      Adenoma                                                                    1 (2%)       1 (2%)       1 (2%)                   
      Adenoma, Multiple                                                                       1 (2%)                                
      Carcinoma                                                                               1 (2%)                                
      Hepatoblastoma, Metastatic, Liver                                                       1 (2%)                                
      Histiocytic Sarcoma                                           1 (2%)                    1 (2%)                                
      Capsule, Adenoma                                 3 (6%)       7 (14%)      3 (6%)       1 (2%)       1 (2%)                   
      Capsule, Leiomyosarcoma                                                    1 (2%)                                             
   Adrenal Medulla                                    (49)         (49)         (49)         (50)         (48)                      
      Pheochromocytoma Malignant                       1 (2%)                                                                       
      Pheochromocytoma Benign                                                                              1 (2%)                   
   Islets, Pancreatic                                 (49)         (50)         (50)         (50)         (48)                      
      Adenoma                                          3 (6%)                                                                       
   Pituitary Gland                                    (49)         (47)         (48)         (46)         (47)                      
      Pars Distalis, Adenoma                           1 (2%)                                              1 (2%)                   
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0            0.1          0.3          1.0          3.0                          
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - cont                                                                                                             
      Pars Intermedia, Adenoma                                      1 (2%)                                                          
   Thyroid Gland                                      (49)         (50)         (49)         (50)         (50)                      
      Follicular Cell, Adenoma                                      2 (4%)       2 (4%)       1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Tissue NOS                                                      (2)                       (1)          (1)                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Coagulating Gland                                                                         (1)                                    
      Histiocytic Sarcoma                                                                     1 (100%)                              
   Epididymis                                         (50)         (50)         (50)         (50)         (50)                      
      Hemangiosarcoma                                                            1 (2%)                                             
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Preputial Gland                                    (50)         (50)         (50)         (50)         (50)                      
      Adenoma                                          1 (2%)                                                                       
   Prostate                                           (50)         (50)         (50)         (50)         (50)                      
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Testes                                             (50)         (50)         (50)         (50)         (50)                      
      Interstitial Cell, Adenoma                                                                           2 (4%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)         (50)         (50)         (50)         (50)                      
      Hemangiosarcoma                                  1 (2%)                                              1 (2%)                   
      Histiocytic Sarcoma                                                                     2 (4%)                                
      Sarcoma                                                       1 (2%)                                                          
   Lymph Node                                         (2)          (3)          (4)          (7)          (4)                       
      Bronchial, Alveolar/Bronchiolar Carcinoma,                                                                                    
           Metastatic, Lung                                                                                1 (25%)                  
      Bronchial, Hepatoblastoma, Metastatic, Liver                                            1 (14%)                               
      Inguinal, Histiocytic Sarcoma                                 1 (33%)                                                         
      Mediastinal, Histiocytic Sarcoma                              2 (67%)                   1 (14%)                               
      Renal, Histiocytic Sarcoma                                    2 (67%)                   1 (14%)                               
   Lymph Node, Mandibular                             (49)         (48)         (49)         (49)         (44)                      
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Lymph Node, Mesenteric                             (49)         (48)         (48)         (50)         (50)                      
      Hemangiosarcoma                                               1 (2%)                                                          
      Hepatoblastoma, Metastatic, Liver                                                       1 (2%)                                
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0            0.1          0.3          1.0          3.0                          
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - cont                                                                                                         
      Histiocytic Sarcoma                                           3 (6%)                    4 (8%)                                
      Leiomyosarcoma                                                             1 (2%)                                             
   Spleen                                             (49)         (49)         (50)         (50)         (49)                      
      Hemangiosarcoma                                  1 (2%)                    3 (6%)       1 (2%)       2 (4%)                   
      Histiocytic Sarcoma                                           2 (4%)       1 (2%)       2 (4%)                                
   Thymus                                             (42)         (46)         (45)         (43)         (43)                      
      Histiocytic Sarcoma                                           1 (2%)       1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (50)         (50)         (50)         (50)         (49)                      
      Subcutaneous Tissue, Fibrosarcoma, Multiple                                1 (2%)                                             
      Subcutaneous Tissue, Sarcoma                                  1 (2%)                                                          
      Subcutaneous Tissue, Sarcoma, Metastatic,                                                                                     
           Skeletal Muscle                                                                                 1 (2%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                                                           (2)          (1)                       
      Hemangiosarcoma                                                                         1 (50%)                               
      Sarcoma, Multiple                                                                                    1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (50)         (50)         (50)         (50)         (50)                      
      Meninges, Histiocytic Sarcoma                                 1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (50)         (50)         (50)         (50)                      
      Alveolar/Bronchiolar Adenoma                     8 (16%)      9 (18%)     10 (20%)      5 (10%)     12 (24%)                  
      Alveolar/Bronchiolar Adenoma, Multiple           4 (8%)       1 (2%)       1 (2%)       3 (6%)                                
      Alveolar/Bronchiolar Carcinoma                   3 (6%)       6 (12%)      2 (4%)                    1 (2%)                   
      Alveolar/Bronchiolar Carcinoma, Multiple         4 (8%)       2 (4%)       4 (8%)       1 (2%)       4 (8%)                   
      Carcinoma, Metastatic, Harderian Gland           2 (4%)                                                                       
      Carcinoma, Metastatic, Uncertain Primary Site                              1 (2%)                                             
      Fibrosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                                                             1 (2%)                   
      Hemangiosarcoma, Metastatic, Liver                                                      1 (2%)       5 (10%)                  
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0            0.1          0.3          1.0          3.0                          
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
RESPIRATORY SYSTEM - cont                                                                                                           
      Hepatoblastoma, Metastatic, Liver                                                       1 (2%)                                
      Hepatocellular Carcinoma, Metastatic, Liver      6 (12%)      6 (12%)      4 (8%)       8 (16%)                               
      Histiocytic Sarcoma                                           2 (4%)       1 (2%)       2 (4%)                                
      Sarcoma, Metastatic, Skeletal Muscle                                                                 1 (2%)                   
      Mediastinum, Histiocytic Sarcoma                              1 (2%)                    1 (2%)                                
   Nose                                               (50)         (50)         (50)         (50)         (50)                      
      Histiocytic Sarcoma                                                                     1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (6)          (1)          (7)          (8)          (3)                       
      Adenoma                                          4 (67%)      1 (100%)     6 (86%)      8 (100%)     2 (67%)                  
      Carcinoma                                        2 (33%)                   1 (14%)      1 (13%)      1 (33%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (49)         (49)         (50)         (50)         (50)                      
      Carcinoma                                                                                            1 (2%)                   
      Hepatoblastoma, Metastatic, Liver                                                       1 (2%)                                
      Hepatocellular Carcinoma, Metastatic, Liver      1 (2%)                                                                       
      Histiocytic Sarcoma                                           1 (2%)       1 (2%)       4 (8%)                                
      Capsule, Hemangiosarcoma                                                                             1 (2%)                   
      Renal Tubule, Adenoma                            1 (2%)                                                                       
   Urinary Bladder                                    (50)         (50)         (50)         (50)         (50)                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)        *(50)                      
      Histiocytic Sarcoma                                           3 (6%)       3 (6%)       4 (8%)                                
      Lymphoma Malignant                               3 (6%)       2 (4%)       1 (2%)       3 (6%)       2 (4%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  12                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 11/30/00  
Route: GAVAGE                                                                                                     Time: 08:16:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0            0.1          0.3          1.0          3.0                          
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            44          45          47          42          47                           
     Total Primary Neoplasms                           85          79          82          64          69                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                 32          27          28          23          17                           
     Total Benign Neoplasms                            42          39          37          27          20                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms              29          31          30          33          41                           
     Total Malignant Neoplasms                         43          40          45          37          49                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              8           6           5          10           7                           
     Total Metastatic Neoplasm                         10           6           5          20          11                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                       1                       1                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  13                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------